Form 4: Climb Bio Director Receives Stock Option Grant

Director Andrew David Levin was granted 40,000 stock options in Climb Bio, Inc. to be held for the benefit of RA Capital Management.

Summary

• Director Andrew David Levin received a grant of 40,000 stock options on June 5, 2026.
• The options have an exercise price of $10.55 per share.
• The options are set to expire on June 4, 2036.
• The reporting person disclaims beneficial ownership, as the options are held for the benefit of various RA Capital Management funds.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant signal regarding company performance.

Positives

• Alignment of director interests with long-term equity performance through option grants.

Negatives

• None identified in this filing.

Risks

• Vesting is subject to the reporting person's continued service through the earlier of June 5, 2027, or the date of the next annual meeting.

Future Outlook

The options vest on the earlier of June 5, 2027, or the day before the next annual meeting of stockholders, contingent on continued service.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices intended to align board member incentives with shareholder value creation, particularly in the biotechnology sector.

Comparison to Industry Standards

• The grant of stock options to non-executive directors is a common practice among small-to-mid-cap biotech firms to attract and retain industry expertise.
• The vesting schedule is consistent with standard one-year cliff or annual meeting-based vesting cycles for board members.

Related Party Transactions

• The reporting person holds the options for the benefit of RA Capital Management, L.P. and its associated funds, and is obligated to turn over any proceeds to the Adviser.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation event for a director.

Next Steps

• Vesting of options on June 5, 2027, or the date of the next annual meeting.

Key Dates

Keywords

Climb Bio, CLYM, Form 4, Stock Options, Insider Trading, Director Compensation